health

A major milestone has been reached for solengepras (also called CVN424), an experimental pill being tested as an add-on treatment for Parkinson's disease. The company Cerevance has announced that all 341 participants have been enrolled in the Phase 3 ARISE trial — meaning the trial is now running at full capacity across 94 sites in the US, Europe, the UK, and Australia. This is a progress update from a press release, not a results announcement: no new efficacy data have been reported yet.

Solengepras works differently from most current Parkinson's medications. Most treatments target the dopamine system directly — either by boosting dopamine levels (levodopa) or mimicking its effects. Solengepras instead blocks a receptor called GPR6, found on nerve cells in the striatum (the brain region that controls voluntary movement). By silencing GPR6, the drug is designed to produce levodopa-like benefits without directly touching dopamine, which researchers hope will reduce two common side effects of long-term levodopa use: off periods (windows when medication wears off and symptoms return) and dyskinesia (sudden, uncontrolled movements). In an earlier Phase 2 trial, solengepras significantly reduced daily off time and increased "good on time" — periods when symptoms are well-controlled — when added to levodopa.

For people living with Parkinson's who struggle with motor fluctuations (averaging 3 or more hours of off time per day), this trial is relevant. The Phase 3 trial tests two doses (75 mg and 150 mg once daily) over 12 weeks, with topline results expected by the end of Q3 2026 — likely September or October this year. If those results are positive, a regulatory submission could follow, though approval would still be at least a year or two away. This is not yet a treatment to ask your doctor about prescribing, but it is one worth watching: if the data hold up, solengepras could be the first genuinely non-dopaminergic oral therapy for off-time management in decades.